CRO

Theia Studios Secures $2.4M to Create a Decentralized Modding Platform Intended to Revolutionize Strategy Games

Retrieved on: 
Wednesday, November 9, 2022

OAKLAND, Calif., Nov. 9, 2022 /PRNewswire/ -- Theia Studios has raised $2.4M to create a web3 creator platform for turn-based strategy games.

Key Points: 
  • OAKLAND, Calif., Nov. 9, 2022 /PRNewswire/ -- Theia Studios has raised $2.4M to create a web3 creator platform for turn-based strategy games.
  • The studio, launched by the co-founders of the popular social fantasy esports platform DraftBuff, will also develop the first games in the Theia ecosystem.
  • The first in this line of games will be the innovative Icons of Theia, whose closed beta will begin on November 10th.
  • Theia's toolkit includes a map editor, asset pipeline, scripting framework, economy builder, and more, which collectively empower creators to create and monetize their own strategy games.

Study Finds AI and Machine Learning Will Be Key for DTC Subscription Service Success

Retrieved on: 
Wednesday, November 9, 2022

SAN FRANCISCO, Nov. 9, 2022 /PRNewswire/ -- Intellimize, the first and only programmatic conversion rate optimization platform (CRO), today released a co-branded eTail study, 'How Brands Can Succeed In The Subscription Economy.'

Key Points: 
  • As many as 75% of direct-to-consumer (DTC) brands are predicted to have a subscription based offering by 20231.
  • The study found that scaling personalization for every visitor, using AI and machine learning, will provide these brands the greatest opportunity to stand out and efficiently achieve their revenue targets.
  • The study indicated that subscription services are growing in popularity as consumers seek simplified ways to streamline their shopping and repurchasing process.
  • Several of the respondents agree that AI offers the most promising future for their subscription sites, especially in terms of personalization.

Excelya Advances Clinical Data Management with Veeva Vault EDC

Retrieved on: 
Wednesday, November 9, 2022

BARCELONA, Spain, Nov. 9, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Excelya is using Vault EDC for electronic data capture (EDC), data cleaning, and reporting in clinical trials. The full-service contract research organization (CRO) will benefit from faster database build cycles and zero downtime when making mid-study design amendments.

Key Points: 
  • BARCELONA, Spain, Nov. 9, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Excelya is using Vault EDC for electronic data capture (EDC) , data cleaning, and reporting in clinical trials.
  • By optimizing clinical data capture with Vault EDC, Excelya now has a system in place to accelerate the design and execution of high-quality trials.
  • Excelya is also leveraging Veeva RTSM for full randomization and trial supply management, integrated with Vault EDC to further streamline data workflows.
  • "Effective data capture is key to running successful clinical trials," said Paul MacDonald, senior director of strategy, Veeva Vault CDMS.

LumaBridge Welcomes Dr. Alexander Stojadinovic as Chief Medical Officer

Retrieved on: 
Tuesday, November 8, 2022

SAN ANTONIO, Nov. 8, 2022 /PRNewswire/ -- LumaBridge (formerly known as Cancer Insight), a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to cancer therapies, welcomes a new chief medical officer, Alexander Stojadinovic, MD, MBA, MSc, FACS.

Key Points: 
  • SAN ANTONIO, Nov. 8, 2022 /PRNewswire/ -- LumaBridge (formerly known as Cancer Insight), a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to cancer therapies, welcomes a new chief medical officer, Alexander Stojadinovic, MD, MBA, MSc, FACS.
  • He brings to LumaBridge his extensive experience in strategic planning, program development, team building, operations, and research and development.
  • Dr. Stojadinovic has served as senior medical director in oncology clinical development at GlaxoSmithKline, as medical director of healthcare management services for Amerigroup Texas, and as a consulting surgical oncologist and healthcare executive.
  • "We are thrilled to welcome Alex to the team," said George E. Peoples, MD, FACS, founder, chief scientific officer, and executive chairman of LumaBridge.

THE CANADIAN INFLAMMATORY BOWEL DISEASE RESEARCH CONSORTIUM AWARDS FIRST $1M PIONEER GRANT FROM TAKEDA CANADA

Retrieved on: 
Tuesday, November 8, 2022

Funding will support the first active comparator, multicentre, randomized trial to evaluate optimal first-line treatment strategy for Ileal Crohn's disease

Key Points: 
  • Funding will support the first active comparator, multicentre, randomized trial to evaluate optimal first-line treatment strategy for Ileal Crohn's disease
    TORONTO, Nov. 8, 2022 /CNW/ - The Canadian Inflammatory Bowel Disease Research Consortium (CIRC) awards the inaugural $1 million PIONEER Grant from Takeda Canada Inc. (Takeda), in support of high-quality, impactful Canadian clinical research to improve patient outcomes and quality of life for people living with inflammatory bowel disease (IBD).
  • The grant awardee will also receive assistance from Alimentiv, a world-class research organization with deep expertise in conducting clinical trials in IBD, through expertise, research execution and in-kind support.
  • Ileal CD increases the risk for bowel damage so choosing the right medical treatment is critical for preventing complications like hospitalization and surgery.
  • "At Takeda, we are committed to advancing scientific research in the area of IBD and are proud to establish the CIRC PIONEER Grant to support Canadian researchers in their pursuit of life-changing innovations," said Rute Fernandes, General Manager, Takeda Canada.

Wib Raises $16 Million Investment to Accelerate Growth and Tackle Rising API Security Problem

Retrieved on: 
Tuesday, November 8, 2022

TEL AVIV, Israel, Nov. 8, 2022 /PRNewswire/ -- Wib, the fast-growth cybersecurity startup pioneering a new era in API security, today announced a $16 million investment led by Koch Disruptive Technologies (KDT), the growth and venture arm of Koch Industries, Inc, with participation from Kmehin Ventures, Venture Israel, Techstars and existing investors. The investment will be used to enhance Wib's pioneering holistic API security platform and accelerate international growth as it expands operations across the Americas, UK and EMEA.

Key Points: 
  • The investment will be used to enhance Wib's pioneering holistic API security platform and accelerate international growth as it expands operations across the Americas, UK and EMEA.
  • Traditional API security solutions are siloed and fragmented, leaving CIOs with a choice of multiple point products or bolt-on integrations to create a patchworked solution.
  • The Wib platform has been purposely built for an API driven world creating a new category of API native security."
  • Wib is pioneering a new era in API security with its industry first holistic API security platform.

Wib Raises $16 Million Investment to Accelerate Growth and Tackle Rising API Security Problem

Retrieved on: 
Tuesday, November 8, 2022

TEL AVIV, Israel, Nov. 8, 2022 /PRNewswire/ -- Wib, the fast-growth cybersecurity startup pioneering a new era in API security, today announced a $16 million investment led by Koch Disruptive Technologies (KDT), the growth and venture arm of Koch Industries, Inc, with participation from Kmehin Ventures, Venture Israel, Techstars and existing investors. The investment will be used to enhance Wib's pioneering holistic API security platform and accelerate international growth as it expands operations across the Americas, UK and EMEA.

Key Points: 
  • The investment will be used to enhance Wib's pioneering holistic API security platform and accelerate international growth as it expands operations across the Americas, UK and EMEA.
  • Traditional API security solutions are siloed and fragmented, leaving CIOs with a choice of multiple point products or bolt-on integrations to create a patchworked solution.
  • The Wib platform has been purposely built for an API driven world creating a new category of API native security."
  • Wib is pioneering a new era in API security with its industry first holistic API security platform.

Robert A. Hauser, MD, MBA, of the Parkinson's Disease and Movement Disorders Center, University of South Florida, joins Vial's Neurology CRO Scientific Advisory Board

Retrieved on: 
Tuesday, November 8, 2022

Dr. Hauser is the Director of the Parkinson's Disease and Movement Disorder Center and a Professor of Neurology at the University of South Florida.

Key Points: 
  • Dr. Hauser is the Director of the Parkinson's Disease and Movement Disorder Center and a Professor of Neurology at the University of South Florida.
  • "We are thrilled to welcome Dr. Hauser to our Neurology CRO as a scientific advisor.
  • Dr. Hauser is board certified in Neurology and has gained international recognition through his research on movement disorders.
  • Vial operates across multiple Therapeutic Areas ( Dermatology CRO , Ophthalmology CRO , Oncology CRO , Gastroenterology CRO , Neurology CRO , Cardiology CRO ).

New Kit Predicts Retroviral Particle Clearance in Biopharmaceutical Manufacturing

Retrieved on: 
Monday, November 7, 2022

This kit enables bioprocess scientists to quantify the removal of Retrovirus-Like Particles (RVLPs) produced endogenously by Chinese Hamster Ovary (CHO) cell lines during biopharmaceutical manufacturing.

Key Points: 
  • This kit enables bioprocess scientists to quantify the removal of Retrovirus-Like Particles (RVLPs) produced endogenously by Chinese Hamster Ovary (CHO) cell lines during biopharmaceutical manufacturing.
  • Viral contamination is an inherent risk during the manufacture of biopharmaceutical products such as antibodies, gene therapies, vaccines, and plasma derivatives.
  • Whether introduced initially from raw materials or later through specific manufacturing operations, unmitigated viral contamination has led to serious health implications and plant shutdowns.
  • With the availability of the MockV RVLP Kit, biopharmaceutical companies can now independently assess the removal of the original retroviral particle of regulatory concern, derived directly from CHO cells.

PowerSchool Appoints New Leadership Positions to Lead Continued Company Growth

Retrieved on: 
Monday, November 7, 2022

Prior to joining PowerSchool, Shander held financial and operational leadership roles at Red Hat, IBM, and Lenovo.

Key Points: 
  • Prior to joining PowerSchool, Shander held financial and operational leadership roles at Red Hat, IBM, and Lenovo.
  • In addition, PowerSchool announced today that Tony Kender joins the company as Chief Revenue Officer (CRO).
  • There he led the business back to revenue growth and delivered their best growth year in company history.
  • PowerSchool.